Asia Pac Allergy.  2012 Jan;2(1):15-25. 10.5415/apallergy.2012.2.1.15.

Progress in the management of childhood asthma

• Vichyanond P
• Pensrichon R
• Kurasirikul S

• KMID: 2397407
• DOI: http://doi.org/10.5415/apallergy.2012.2.1.15

Abstract

Asthma has become the most common chronic disease in childhood. Significant advances in epidemiological research as well as in therapy of pediatric asthma have been made over the past 2 decades. In this review, we look at certain aspects therapy of childhood asthma, both in the past and present. Literature review on allergen avoidance (including mites, cockroach and cat), intensive therapy with β₂-agonists in acute asthma (administering via continuous nebulization and intravenous routes), a revisit of theophylline use and its action, the use of inhaled corticosteroids in various phases of childhood asthma and sublingual immunotherapy in asthma are examined. Recent facts and dilemmas of these treatments are identified along with expression of our opinions, particularly on points of childhood asthma in the Asia-Pacific, are made in this review.

Keyword

Asthma; Children; β₂-agonist; Theophylline; Inhaled corticosteroids; Sublingual immunotherapy

MeSH Terms

Adrenal Cortex Hormones
Asthma*
Child
Chronic Disease
Cockroaches
Humans
Mites
Sublingual Immunotherapy
Theophylline
Adrenal Cortex Hormones
Theophylline

Reference

1. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet. 1998. 351:1225–1232.

2. Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK, Williams H. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006. 368:733–743.

3. National Heart, Lung, and Blood Institute. Expert panel report 3: guidelines for the diagnosis and management of asthma-full report 2007. August 28, 2007. Available from: www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf.

4. Bacharier LB, Boner A, Carlsen KH, Eigenmann PA, Frischer T, Götz M, Helms PJ, Hunt J, Liu A, Papadopoulos N, Platts-Mills T, Pohunek P, Simons FE, Valovirta E, Wahn U, Wildhaber J. Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy. 2008. 63:5–34.

5. Kroegel C. Global Initiative for Asthma (GINA) guidelines: 15 years of application. Expert Rev Clin Immunol. 2009. 5:239–249.

6. Morgan WJ, Crain EF, Gruchalla RS, O'Connor GT, Kattan M, Evans R 3rd, Stout J, Malindzak G, Smartt E, Plaut M, Walter M, Vaughn B, Mitchell H. Results of a home-based environmental intervention among urban children with asthma. N Engl J Med. 2004. 351:1068–1080.

7. Gøtzsche PC, Johansen HK. House dust mite control measures for asthma: systematic review. Allergy. 2008. 63:646–659.

8. Platts-Mills TA. Allergen avoidance in the treatment of asthma: problems with the meta-analyses. J Allergy Clin Immunol. 2008. 122:694–696.

9. Platts-Mills TA, Vervloet D, Thomas WR, Aalberse RC, Chapman MD. Indoor allergens and asthma: report of the Third International Workshop. J Allergy Clin Immunol. 1997. 100:S2–S24.

10. Squillace SP, Sporik RB, Rakes G, Couture N, Lawrence A, Merriam S, Zhang J, Platts-Mills AE. Sensitization to dust mites as a dominant risk factor for asthma among adolescents living in central Virginia. Multiple regression analysis of a population-based study. Am J Respir Crit Care Med. 1997. 156:1760–1764.

11. Sterk PJ, Buist SA, Woolcock AJ, Marks GB, Platts-Mills TA, von Mutius E, Bousquet J, Frew AJ, Pauwels RA, Aït-Khaled N, Hill SL, Partridge MR. The message from the World Asthma Meeting. The Working Groups of the World Asthma Meeting, held in Barcelona, Spain, December 9-13, 1998. Eur Respir J. 1999. 14:1435–1453.

12. Peat JK, Li J. Reversing the trend: reducing the prevalence of asthma. J Allergy Clin Immunol. 1999. 103:1–10.

13. Vaughan JW, McLaughlin TE, Perzanowski MS, Platts-Mills TA. Evaluation of materials used for bedding encasement: effect of pore size in blocking cat and dust mite allergen. J Allergy Clin Immunol. 1999. 103:227–231.

14. Frederick JM, Warner JO, Jessop WJ, Enander I, Warner JA. Effect of a bed covering system in children with asthma and house dust mite hypersensitivity. Eur Respir J. 1997. 10:361–366.

15. Halken S, Høst A, Niklassen U, Hansen LG, Nielsen F, Pedersen S, Osterballe O, Veggerby C, Poulsen LK. Effect of mattress and pillow encasings on children with asthma and house dust mite allergy. J Allergy Clin Immunol. 2003. 111:169–176.

16. McDonald LG, Tovey E. The role of water temperature and laundry procedures in reducing house dust mite populations and allergen content of bedding. J Allergy Clin Immunol. 1992. 90:599–608.

17. Bush RK. Does allergen avoidance work? Immunol Allergy Clin North Am. 2011. 31:493–507.

18. Tovey ER, Woolcock AJ. Direct exposure of carpets to sunlight can kill all mites. J Allergy Clin Immunol. 1994. 93:1072–1074.

19. Rosenstreich DL, Eggleston P, Kattan M, Baker D, Slavin RG, Gergen P, Mitchell H, McNiff-Mortimer K, Lynn H, Ownby D, Malveaux F. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. N Engl J Med. 1997. 336:1356–1363.

20. Tungtrongchitr A, Sookrung N, Munkong N, Mahakittikun V, Chinabut P, Chaicumpa W, Bunnag C, Vichyanond P. The levels of cockroach allergen in relation to cockroach species and allergic diseases in Thai patients. Asian Pac J Allergy Immunol. 2004. 22:115–121.

21. Eggleston PA. Cockroach allergen abatement in inner-city homes. Ann Allergy Asthma Immunol. 2003. 91:512–514.

22. Arbes SJ Jr, Sever M, Mehta J, Gore JC, Schal C, Vaughn B, Mitchell H, Zeldin DC. Abatement of cockroach allergens (Bla g 1 and Bla g 2) in low-income, urban housing: month 12 continuation results. J Allergy Clin Immunol. 2004. 113:109–114.

23. Sever ML, Arbes SJ Jr, Gore JC, Santangelo RG, Vaughn B, Mitchell H, Schal C, Zeldin DC. Cockroach allergen reduction by cockroach control alone in low-income urban homes: a randomized control trial. J Allergy Clin Immunol. 2007. 120:849–855.

24. Gent JF, Belanger K, Triche EW, Bracken MB, Beckett WS, Leaderer BP. Association of pediatric asthma severity with exposure to common household dust allergens. Environ Res. 2009. 109:768–774.

25. Wallace DV. Pet dander and perennial allergic rhinitis: therapeutic options. Allergy Asthma Proc. 2009. 30:573–583.

26. Wood RA, Chapman MD, Adkinson NF Jr, Eggleston PA. The effect of cat removal on allergen content in household-dust samples. J Allergy Clin Immunol. 1989. 83:730–734.

27. Hodson T, Custovic A, Simpson A, Chapman M, Woodcock A, Green R. Washing the dog reduces dog allergen levels, but the dog needs to be washed twice a week. J Allergy Clin Immunol. 1999. 103:581–585.

28. Wood RA, Johnson EF, Van Natta ML, Chen PH, Eggleston PA. A placebo-controlled trial of a HEPA air cleaner in the treatment of cat allergy. Am J Respir Crit Care Med. 1998. 158:115–120.

29. Kilburn S, Lasserson TJ, McKean M. Pet allergen control measures for allergic asthma in children and adults. Cochrane Database Syst Rev. 2003. CD002989.

30. Moler FW, Hurwitz ME, Custer JR. Improvement in clinical asthma score and PaCO2 in children with severe asthma treated with continuously nebulized terbutaline. J Allergy Clin Immunol. 1988. 81:1101–1109.

31. Portnoy J, Aggarwal J. Continuous terbutaline nebulization for the treatment of severe exacerbations of asthma in children. Ann Allergy. 1988. 60:368–371.

32. Portnoy J, Nadel G, Amado M, Willsie-Ediger S. Continuous nebulization for status asthmaticus. Ann Allergy. 1992. 69:71–79.

33. Papo MC, Frank J, Thompson AE. A prospective, randomized study of continuous versus intermittent nebulized albuterol for severe status asthmaticus in children. Crit Care Med. 1993. 21:1479–1486.

34. Khine H, Fuchs SM, Saville AL. Continuous vs intermittent nebulized albuterol for emergency management of asthma. Acad Emerg Med. 1996. 3:1019–1024.

35. Rodrigo GJ, Rodrigo C. Continuous vs intermittent beta-agonists in the treatment of acute adult asthma: a systematic review with meta-analysis. Chest. 2002. 122:160–165.

36. Rudnitsky GS, Eberlein RS, Schoffstall JM, Mazur JE, Spivey WH. Comparison of intermittent and continuously nebulized albuterol for treatment of asthma in an urban emergency department. Ann Emerg Med. 1993. 22:1842–1846.

37. Camargo CA Jr, Spooner CH, Rowe BH. Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane Database Syst Rev. 2003. CD001115.

38. Stephanopoulos DE, Monge R, Schell KH, Wyckoff P, Peterson BM. Continuous intravenous terbutaline for pediatric status asthmaticus. Crit Care Med. 1998. 26:1744–1748.

39. Browne GJ, Trieu L, Van Asperen P. Randomized, double-blind, placebo-controlled trial of intravenous salbutamol and nebulized ipratropium bromide in early management of severe acute asthma in children presenting to an emergency department. Crit Care Med. 2002. 30:448–453.

40. Kambalapalli M, Nichani S, Upadhyayula S. Safety of intravenous terbutaline in acute severe asthma: a retrospective study. Acta Paediatr. 2005. 94:1214–1217.

41. Beveridge RC, Grunfeld AF, Hodder RV, Verbeek PR. Guidelines for the emergency management of asthma in adults. CAEP/CTS Asthma Advisory Committee. Canadian Association of Emergency Physicians and the Canadian Thoracic Society. CMAJ. 1996. 155:25–37.

42. Lipworth BJ. Treatment of acute asthma. Lancet. 1997. 350:Suppl 2. SII18–SII23.

43. Travers AH, Rowe BH, Barker S, Jones A, Camargo CA Jr. The effectiveness of IV beta-agonists in treating patients with acute asthma in the emergency department: a meta-analysis. Chest. 2002. 122:1200–1207.

44. Hirsch S. Klinischer und experimenteller beitrag zur Krampflösenden wirkung der purinderivate. Klin Wochenschr. 1922. 1:615–618.

45. Herrmann G, Aynesworth MB. Successful treatment of persistent extreme dyspnea "status asthmaticus". Use of theophylline ethylene diamine (aminophylline, U. S. P.) intravenously. 1938. J Lab Clin Med. 1990. 115:512–525.

46. Brown EA. A new type of medication to be used in bronchial asthma and other allergic conditions - preliminary note. N Engl J Med. 1940. 223:843–846.

47. Weinberger M, Hendeles L, Bighley L. The relation of product formulation to absorption of oral theophylline. N Engl J Med. 1978. 299:852–857.

48. Katz RM, Rachelefsky GS, Siegel SC, Mickey R. Theophylline administration in children with asthma: optimal pulmonary function and possible tolerance to chronic administration. Ann Allergy. 1983. 50:23–26.

49. Siegel D, Sheppard D, Gelb A, Weinberg PF. Aminophylline increases the toxicity but not the efficacy of an inhaled beta-adrenergic agonist in the treatment of acute exacerbations of asthma. Am Rev Respir Dis. 1985. 132:283–286.

50. Yung M, South M. Randomised controlled trial of aminophylline for severe acute asthma. Arch Dis Child. 1998. 79:405–410.

51. Mitra A, Bassler D, Goodman K, Lasserson TJ, Ducharme FM. Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database Syst Rev. 2005. CD001276.

52. Bergstrand H. Phosphodiesterase inhibition and theophylline. Eur J Respir Dis Suppl. 1980. 109:37–44.

53. Miura M, Belvisi MG, Stretton CD, Yacoub MH, Barnes PJ. Role of potassium channels in bronchodilator responses in human airways. Am Rev Respir Dis. 1992. 146:132–136.

54. Pauwels RA, Joos GF. Characterization of the adenosine receptors in the airways. Arch Int Pharmacodyn Ther. 1995. 329:151–160.

55. Murciano D, Aubier M, Lecocguic Y, Pariente R. Effects of theophylline on diaphragmatic strength and fatigue in patients with chronic obstructive pulmonary disease. N Engl J Med. 1984. 311:349–353.

56. Jenne JW, Siever JR, Druz WS, Solano JV, Cohen SM, Sharp JT. The effect of maintenance theophylline therapy on lung work in severe chronic obstructive pulmonary disease while standing and walking. Am Rev Respir Dis. 1984. 130:600–605.

57. Pauwels R, Van Renterghem D, Van der Straeten M, Johannesson N, Persson CG. The effect of theophylline and enprofylline on allergen-induced bronchoconstriction. J Allergy Clin Immunol. 1985. 76:583–590.

58. Sullivan P, Bekir S, Jaffar Z, Page C, Jeffery P, Costello J. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet. 1994. 343:1006–1008.

59. Kraft M, Torvik JA, Trudeau JB, Wenzel SE, Martin RJ. Theophylline: potential antiinflammatory effects in nocturnal asthma. J Allergy Clin Immunol. 1996. 97:1242–1246.

60. Mascali JJ, Cvietusa P, Negri J, Borish L. Anti-inflammatory effects of theophylline: modulation of cytokine production. Ann Allergy Asthma Immunol. 1996. 77:34–38.

61. Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, Barnes PJ. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci U S A. 2002. 99:8921–8926.

62. Marwick JA, Wallis G, Meja K, Kuster B, Bouwmeester T, Chakravarty P, Fletcher D, Whittaker PA, Barnes PJ, Ito K, Adcock IM, Kirkham PA. Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008. 377:797–802.

63. Davies B, Brooks G, Devoy M. The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies. Respir Med. 1998. 92:256–263.

64. Tee AK, Koh MS, Gibson PG, Lasserson TJ, Wilson AJ, Irving LB. Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma. Cochrane Database Syst Rev. 2007. CD001281.

65. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O'Connor BJ, Barnes PJ. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med. 1997. 337:1412–1418.

66. Seddon P, Bara A, Ducharme FM, Lasserson TJ. Oral xanthines as maintenance treatment for asthma in children. Cochrane Database Syst Rev. 2006. CD002885.

67. Volovitz B, Amir J, Malik H, Kauschansky A, Varsano I. Growth and pituitary-adrenal function in children with severe asthma treated with inhaled budesonide. N Engl J Med. 1993. 329:1703–1708.

68. Haahtela T, Järvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Reinikainen K, Selroos O, Sovijärvi A, Stenius-Aarniala B, Svahn T, Tammivaara R, Laitinen LA. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991. 325:388–392.

69. van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, Duiverman EJ, Pocock SJ, Kerrebijn KF. The Dutch Chronic Non-specific Lung Disease Study Group. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. Am Rev Respir Dis. 1992. 146:547–554.

70. Skoner DP, Rachelefsky GS, Meltzer EO, Chervinsky P, Morris RM, Seltzer JM, Storms WW, Wood RA. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics. 2000. 105:E23.

71. Guilbert TW, Mauger DT, Allen DB, Zeiger RS, Lemanske RF Jr, Szefler SJ, Strunk RC, Bacharier LB, Covar R, Sorkness CA, Taussig LM, Martinez FD. Growth of preschool children at high risk for asthma 2 years after discontinuation of fluticasone. J Allergy Clin Immunol. 2011. 128:956–963. e1–e7.

72. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med. 2000. 343:1064–1069.

73. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med. 1998. 339:1194–1200.

74. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med. 1994. 88:373–381.

75. Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, Ullman A, Lamm CJ, O'Byrne PM. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003. 361:1071–1076.

76. Chen YZ, Busse WW, Pedersen S, Tan W, Lamm CJ, O'Byrne PM. Early intervention of recent onset mild persistent asthma in children aged under 11 yrs: the Steroid Treatment As Regular Therapy in early asthma (START) trial. Pediatr Allergy Immunol. 2006. 17:Suppl 17. 7–13.

77. The Childhood Asthma Management Program Research Group. Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med. 2000. 343:1054–1063.

78. Covar RA, Spahn JD, Murphy JR, Szefler SJ. Progression of asthma measured by lung function in the childhood asthma management program. Am J Respir Crit Care Med. 2004. 170:234–241.

79. Castro-Rodríguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med. 2000. 162:1403–1406.

80. Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, Bacharier LB, Lemanske RF Jr, Strunk RC, Allen DB, Bloomberg GR, Heldt G, Krawiec M, Larsen G, Liu AH, Chinchilli VM, Sorkness CA, Taussig LM, Martinez FD. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006. 354:1985–1997.

81. Volovitz B, Bentur L, Finkelstein Y, Mansour Y, Shalitin S, Nussinovitch M, Varsano I. Effectiveness and safety of inhaled corticosteroids in controlling acute asthma attacks in children who were treated in the emergency department: a controlled comparative study with oral prednisolone. J Allergy Clin Immunol. 1998. 102:605–609.

82. Levy ML, Stevenson C, Maslen T. Comparison of short courses of oral prednisolone and fluticasone propionate in the treatment of adults with acute exacerbations of asthma in primary care. Thorax. 1996. 51:1087–1092.

83. Rodrigo G, Rodrigo C. Inhaled flunisolide for acute severe asthma. Am J Respir Crit Care Med. 1998. 157:698–703.

84. Schuh S, Reisman J, Alshehri M, Dupuis A, Corey M, Arseneault R, Alothman G, Tennis O, Canny G. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. N Engl J Med. 2000. 343:689–694.

85. Schuh S, Dick PT, Stephens D, Hartley M, Khaikin S, Rodrigues L, Coates AL. High-dose inhaled fluticasone does not replace oral prednisolone in children with mild to moderate acute asthma. Pediatrics. 2006. 118:644–650.

86. Edmonds ML, Camargo CA Jr, Pollack CV Jr, Rowe BH. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. Cochrane Database Syst Rev. 2003. CD002308.

87. Boushey HA, Sorkness CA, King TS, Sullivan SD, Fahy JV, Lazarus SC, Chinchilli VM, Craig TJ, Dimango EA, Deykin A, Fagan JK, Fish JE, Ford JG, Kraft M, Lemanske RF Jr, Leone FT, Martin RJ, Mauger EA, Pesola GR, Peters SP, Rollings NJ, Szefler SJ, Wechsler ME, Israel E. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med. 2005. 352:1519–1528.

88. Martinez FD, Chinchilli VM, Morgan WJ, Boehmer SJ, Lemanske RF Jr, Mauger DT, Strunk RC, Szefler SJ, Zeiger RS, Bacharier LB, Bade E, Covar RA, Friedman NJ, Guilbert TW, Heidarian-Raissy H, Kelly HW, Malka-Rais J, Mellon MH, Sorkness CA, Taussig L. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet. 2011. 377:650–657.

89. Zeiger RS, Mauger D, Bacharier LB, Guilbert TW, Martinez FD, Lemanske RF Jr, Strunk RC, Covar R, Szefler SJ, Boehmer S, Jackson DJ, Sorkness CA, Gern JE, Kelly HW, Friedman NJ, Mellon MH, Schatz M, Morgan WJ, Chinchilli VM, Raissy HH, Bade E, Malka-Rais J, Beigelman A, Taussig LM. Daily or intermittent budesonide in preschool children with recurrent wheezing. N Engl J Med. 2011. 365:1990–2001.

90. Eifan AO, Akkoc T, Yildiz A, Keles S, Ozdemir C, Bahceciler NN, Barlan IB. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy. 2010. 40:922–932.

91. Ferrés J, Justicia JL, García MP, Muñoz-Tudurí M, Alvà V. Efficacy of high-dose sublingual immunotherapy in children allergic to house dust mites in real-life clinical practice. Allergol Immunopathol (Madr). 2011. 39:122–127.

92. Ma XP, Muzhapaer D. Efficacy of sublingual immunotherapy in children with dust mite allergic asthma. Zhongguo Dang Dai Er Ke Za Zhi. 2010. 12:344–347.

93. Ippoliti F, De Santis W, Volterrani A, Lenti L, Canitano N, Lucarelli S, Frediani T. Immunomodulation during sublingual therapy in allergic children. Pediatr Allergy Immunol. 2003. 14:216–221.

94. Niu CK, Chen WY, Huang JL, Lue KH, Wang JY. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multicenter, double-blind, randomized, and placebo-controlled study in Taiwan. Respir Med. 2006. 100:1374–1383.

95. Lue KH, Lin YH, Sun HL, Lu KH, Hsieh JC, Chou MC. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol. 2006. 17:408–415.

96. Calamita Z, Saconato H, Pelá AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method. Allergy. 2006. 61:1162–1172.

97. Penagos M, Passalacqua G, Compalati E, Baena-Cagnani CE, Orozco S, Pedroza A, Canonica GW. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest. 2008. 133:599–609.

98. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy. 2006. 61:185–190.

99. Pham-Thi N, Scheinmann P, Fadel R, Combebias A, Andre C. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr Allergy Immunol. 2007. 18:47–57.

100. Hirsch T, Sähn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children. Pediatr Allergy Immunol. 1997. 8:21–27.

101. Rienzo VD, Minelli M, Musarra A, Sambugaro R, Pecora S, Canonica WG, Passalacqua G. Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy. 2005. 35:560–564.

102. Pajno GB, Caminiti L, Crisafulli G, Vita D, Valenzise M, De Luca R, Passalacqua G. Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy: a randomized controlled study. Pediatr Allergy Immunol. 2011. 22:803–807.